# NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial

Study · id `cardio:ct-nct02483143` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02483143](<https://clinicaltrials.gov/study/NCT02483143>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02483143

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 231 participants.

## Technical summary

Registry record NCT02483143. Randomized; triple masking; primary purpose prevention. Start 2014-02 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 231 participants (enrolled count; ClinicalTrials.gov record NCT02483143, source copy `cardio:ctgov-nct02483143-2015-06-26`, retrieved 2026-10-31)
- Start date: 2014-02 (registry gives no type) (ClinicalTrials.gov record NCT02483143, source copy `cardio:ctgov-nct02483143-2015-06-26`, retrieved 2026-10-31)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02483143, source copy `cardio:ctgov-nct02483143-2015-06-26`, retrieved 2026-10-31)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02483143, source copy `cardio:ctgov-nct02483143-2015-06-26`, retrieved 2026-10-31)
- Countries: Türkiye (ClinicalTrials.gov record NCT02483143, source copy `cardio:ctgov-nct02483143-2015-06-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02483143-2015-06-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial
- Condition: Radiographic Contrast Agent Nephropathy
- Condition: Pulmonary Embolism
- Intervention (Drug): NAC
- Intervention (Drug): NaHCO3
- Intervention (Drug): Normal Saline
- Lead sponsor: Karadeniz Technical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The High Risk of Contrast-induced Nephropathy in Patients with Suspected Pulmonary Embolism Despite Three Different Prophylaxis: A Randomized Controlled Trial (`cardio:pubmed-27411777`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ff731ee7486fac690ee223595389805cfb3edffac13ea4644d6218433a96e16e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
